Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1157]

Is there a role for androgen deprivation therapy combined with radiotherapy in...

Prof Abdenour Nabid - Sherbrooke University Hospital Centre, Sherbrooke, Canada

Is there a role for androgen deprivation therapy combined with radiotherapy in intermediate risk prostate cancer? ( Prof Abdenour Nabid - Sherbrooke University Hospital Centre, Sherbrooke, Canada )

When and whether to conduct endocrine therapy in non-metastatic prostate cancer

Dr Frederik Birkebæk Thomsen - University of Copenhagen, Copenhagen, Denmark

When and whether to conduct endocrine therapy in non-metastatic prostate cancer ( Dr Frederik Birkebæk Thomsen - University of Copenhagen, Copenhagen, Denmark )

High BMI beneficial in kidney cancer

Dr Laurence Albiges - Dana-Farber Cancer Institute, Boston, USA

High BMI beneficial in kidney cancer ( Dr Laurence Albiges - Dana-Farber Cancer Institute, Boston, USA )

Basal subtype predicts clinical benefit from neoadjuvant chemo in urothelial...

Dr Arlene Siefker-Radtke - MD Anderson Cancer Centre, Houston, USA

Basal subtype predicts clinical benefit from neoadjuvant chemo in urothelial cancer ( Dr Arlene Siefker-Radtke - MD Anderson Cancer Centre, Houston, USA )

New approach to prostate cancer screening

Dr Sanoj Punnen - University of Miami, Miami, USA

New approach to prostate cancer screening ( Dr Sanoj Punnen - University of Miami, Miami, USA )

ASCO GU 2015: Review of the latest data in prostate cancer

Prof Eleni Efstathiou, Prof Charles Ryan, Dr Heather Payne

ASCO GU 2015: Review of the latest data in prostate cancer ( Prof Eleni Efstathiou, Prof Charles Ryan, Dr Heather Payne )

Dose-escalated brachytherapy best treatment for unfavourable-risk localised...

Dr Scott Tyldesley - British Columbia Cancer Agency, Vancouver, Canada

Dose-escalated brachytherapy best treatment for unfavourable-risk localised prostate cancer ( Dr Scott Tyldesley - British Columbia Cancer Agency, Vancouver, Canada )

Combination of pazopanib and paclitaxel safe in urothelial cancer

Prof Sandy Srinivas - Stanford University Medical Centre, Stanford, USA

Combination of pazopanib and paclitaxel safe in urothelial cancer ( Prof Sandy Srinivas - Stanford University Medical Centre, Stanford, USA )

Tackling renal cancer with a combination of autologous immunotherapy and...

Prof Robert Figlin - Cedars-Sinai, Los Angeles, USA

Tackling renal cancer with a combination of autologous immunotherapy and sunitinib ( Prof Robert Figlin - Cedars-Sinai, Los Angeles, USA )

ASCO GU 2015: Prostate highlights from day one

Prof Karim Fizazi, Prof Kurt Miller, Dr Maria De Santis, Dr Mark Rubin

ASCO GU 2015: Prostate highlights from day one ( Prof Karim Fizazi, Prof Kurt Miller, Dr Maria De Santis, Dr Mark Rubin )

Challenging results from mTOR inhibitors in metastatic clear cell renal cancer

Prof Thomas Powles - Barts Health, London, UK

Challenging results from mTOR inhibitors in metastatic clear cell renal cancer ( Prof Thomas Powles - Barts Health, London, UK )

Metastatic prostate cancer - Interpreting negative trial results

Prof Stephane Oudard and Prof Noel Clarke

Metastatic prostate cancer - Interpreting negative trial results ( Prof Stephane Oudard and Prof Noel Clarke )

More from ecancer